Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h): sc-402753-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h) and Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CHRNA9. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Antibody (8E4): sc-293282
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h) | sc-402753-NIC | 20 µg | $410.00 | |||
Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h2) | sc-402753-NIC-2 | 20 µg | $410.00 |
CHRNA9 encodes the α9 subunit of the nicotinic acetylcholine receptor, a ligand-gated cation channel that forms functional receptors (often with α10) to couple cholinergic cues to membrane depolarization and Ca²⁺-dependent signaling. In human tissues, α9-containing nAChRs regulate excitability and intracellular calcium dynamics, influencing downstream pathways such as MAPK/ERK and other activity-dependent transcriptional programs. CHRNA9 expression has been studied in sensory and epithelial contexts, including auditory hair cell physiology and broader cholinergic signaling networks relevant to cell communication and stress responses. Altered CHRNA9 regulation has been reported across disease-oriented research settings, supporting its use as a mechanistic target for dissecting cholinergic ion channel biology in human model systems.
Nicotinic Acetylcholine Receptor alpha 9/CHRNA9 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CHRNA9 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CHRNA9. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CHRNA9 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CHRNA9-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.